PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling

Metastatic prostate cancer (PCa) has high mortality and a poor 5-year survival rate primarily due to the lack of effective treatments. Bone is the primary site of PCa metastasis in humans and the development of reliable therapeutic options for bone metastatic PCa will make a huge impact in reducing...

Full description

Saved in:
Bibliographic Details
Published in:Biochem Pharmacol
Main Authors: Verma, Arti, Artham, Sandeep, Alwhaibi, Abdulrahman, Adil, Mir S., Cummings, Brian S., Somanath, Payaningal R.
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7414983/
https://ncbi.nlm.nih.gov/pubmed/32240651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2020.113943
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items